Neurological Disorders

Todd Levine

Publications

• Research Article
  H.P. Acthar® Gel in Dermatomyositis and Polymyositis Treatment Registry: An Interim Analysis
  Author(s): Todd Levine, Justin Malone, Petros Efthimiou, Rup Tandan, Ara Dikranian, Aidan Levine and David SapersteinTodd Levine, Justin Malone, Petros Efthimiou, Rup Tandan, Ara Dikranian, Aidan Levine and David Saperstein
  
  Introduction: Therapies for dermatomyositis and polymyositis (DM/PM) include corticosteroids, immunosuppressants, and intravenous immunoglobulin (IVIg). A high proportion of patients with DM/PM are refractory to therapy. H.P. Acthar® Gel, repository corticotropin injection (RCI) is a potential anti-inflammatory treatment. Methods: Patients enrolled in the Acthar in Dermatomyositis and Polymyositis Treatment registry were monitored for changes in the clinical parameters of DM/PM after initiation of RCI twice weekly in doses up to 80 IU per subcutaneous injection. Results: RCI treatment effectively altered the clinical course of DM/PM in 14 of 24 patients. Positive responses to treatment were associated with disease activity at baseline and duration of treatment. Mild to moderate adverse events were reported... Read More»
  DOI: 10.4172/2329-6895.1000292

  Abstract PDF